Literature DB >> 10072711

NO: the primary EDRF.

I Fleming1, R Busse.   

Abstract

Since the discovery of an endothelium-derived relaxing factor (EDRF) by Furchgott and Zawadzki (Furchgott and Zawadzki. 1980), which was later identified as nitric oxide (NO) (Ignarro et al., 1987; Palmer et al., 1987; Furchgott, 1988), it has become clear that there are a number of additional endothelium-derived vasodilator and vasoconstrictor autacoids (endothelin-1, prostaglandin H2, and the endothelium-derived hyperpolarizing factor: EDHF). None of these autacoids play such a central role in the regulation of vascular tone and homeostasis as the primary EDRF, the free radical NO, which is generated via a live-electron oxidation of a guanidino nitrogen from L-arginine by an NO synthase (NOS).

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10072711     DOI: 10.1006/jmcc.1998.0839

Source DB:  PubMed          Journal:  J Mol Cell Cardiol        ISSN: 0022-2828            Impact factor:   5.000


  46 in total

1.  Improved pulmonary vascular reactivity and decreased hypertrophic remodeling during nonhypercapnic acidosis in experimental pulmonary hypertension.

Authors:  Helen Christou; Ossama M Reslan; Virak Mam; Alain F Tanbe; Sally H Vitali; Marlin Touma; Elena Arons; S Alex Mitsialis; Stella Kourembanas; Raouf A Khalil
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2012-01-27       Impact factor: 5.464

2.  Principles for characterizing the potential human health effects from exposure to nanomaterials: elements of a screening strategy.

Authors:  Günter Oberdörster; Andrew Maynard; Ken Donaldson; Vincent Castranova; Julie Fitzpatrick; Kevin Ausman; Janet Carter; Barbara Karn; Wolfgang Kreyling; David Lai; Stephen Olin; Nancy Monteiro-Riviere; David Warheit; Hong Yang
Journal:  Part Fibre Toxicol       Date:  2005-10-06       Impact factor: 9.400

3.  Contraction-initiated NO-dependent lymphatic relaxation: a self-regulatory mechanism in rat thoracic duct.

Authors:  Olga Yu Gasheva; David C Zawieja; Anatoliy A Gashev
Journal:  J Physiol       Date:  2006-06-29       Impact factor: 5.182

Review 4.  Modulators of the vascular endothelin receptor in blood pressure regulation and hypertension.

Authors:  Raouf A Khalil
Journal:  Curr Mol Pharmacol       Date:  2011-11       Impact factor: 3.339

5.  Nitric oxide donors inhibit the coxsackievirus B3 proteinases 2A and 3C in vitro, virus production in cells, and signs of myocarditis in virus-infected mice.

Authors:  Roland Zell; René Markgraf; Michaela Schmidtke; Matthias Görlach; Axel Stelzner; Andreas Henke; Holger H Sigusch; Brigitte Glück
Journal:  Med Microbiol Immunol       Date:  2003-09-26       Impact factor: 3.402

6.  Downregulation of vascular soluble guanylate cyclase induced by high salt intake in spontaneously hypertensive rats.

Authors:  S Kagota; A Tamashiro; Y Yamaguchi; R Sugiura; T Kuno; K Nakamura; M Kunitomo
Journal:  Br J Pharmacol       Date:  2001-10       Impact factor: 8.739

7.  Substance P enhances wound closure in nitric oxide synthase knockout mice.

Authors:  Pornprom Muangman; Richard N Tamura; Lara A Muffley; F Frank Isik; Jeffrey R Scott; Chengyu Xie; Gary Kegel; Stephen R Sullivan; Zhi Liang; Nicole S Gibran
Journal:  J Surg Res       Date:  2008-05-16       Impact factor: 2.192

8.  A mathematical model of vasoreactivity in rat mesenteric arterioles: I. Myoendothelial communication.

Authors:  Adam Kapela; Anastasios Bezerianos; Nikolaos M Tsoukias
Journal:  Microcirculation       Date:  2009-11       Impact factor: 2.628

9.  Subtype-specific estrogen receptor-mediated vasodilator activity in the cephalic, thoracic, and abdominal vasculature of female rat.

Authors:  Ossama M Reslan; Zongzhi Yin; Graciliano R A do Nascimento; Raouf A Khalil
Journal:  J Cardiovasc Pharmacol       Date:  2013-07       Impact factor: 3.105

10.  Increased constrictor tone induced by ouabain treatment in rats.

Authors:  Victor M Pulgar; Anne B Jeffers; Hanadi M Rashad; Debra I Diz; Azeez A Aileru
Journal:  J Cardiovasc Pharmacol       Date:  2013-08       Impact factor: 3.105

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.